The design and validation of a novel phenotypic assay to determine HIV-1 coreceptor usage of clinical isolates

Journal of Virological Methods

Volumn 169, Issue 1, 2010, Pages 39-46

  Lin, Nina H ^a,b,c   Negusse, Daniel M ^d   Beroukhim, Rameen ^e,f   Giguel, Francoise ^a,b,c   Lockman, Shahin ^b,c,d   Essex, Myron ^d   Kuritzkes, Daniel R ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Harvard AIDS Institute   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

CCR5; Chemokine receptor; Coreceptor usage; CXCR4; HIV; Luciferase; Pseudovirus; Viral fitness; Viral tropism

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; LUCIFERASE; VIRUS RNA;

ACCURACY; AMPLICON; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PHENOTYPE; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; VIROGENESIS; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS ISOLATION; VIRUS LOAD;

CELL LINE; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENES, REPORTER; HIV INFECTIONS; HIV-1; HUMANS; LUCIFERASES; PLASMIDS; RECEPTORS, HIV; SENSITIVITY AND SPECIFICITY; VIROLOGY; VIRUS INTERNALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77956185778     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2010.06.012     Document Type: Article

References (27)

1. Braun P., Wiesmann F. Phenotypic assays for the determination of coreceptor tropism in HIV-1 infected individuals. Eur. J. Med. Res. 2007, 12:463-472.
2. Coakley E., Reeves J.D., Huang W., Mangas-Ruiz M., Maurer I., Harskamp A.M., Gupta S., Lie Y., Petropoulos C.J., Schuitemaker H., van't Wout A.B. Comparison of human immunodeficiency virus type 1 tropism profiles in clinical samples by the Trofile and MT-2 assays. Antimicrob. Agents Chemother. 2009, 53:4686-4693.
3. Cocchi F., DeVico A.L., Garzino-Demo A., Cara A., Gallo R.C., Lusso P. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat. Med. 1996, 2:1244-1247.
4. Fang G., Zhu G., Burger H., Keithly J.S., Weiser B. Minimizing DNA recombination during long RT-PCR. J. Virol. Methods 1998, 76:139-148.
5. Fouchier R.A., Groenink M., Kootstra N.A., Tersmette M., Huisman H.G., Miedema F., Schuitemaker H. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J. Virol. 1992, 66:3183-3187.
6. Gulick R.M., Su Z., Flexner C., Hughes M.D., Skolnik P.R., Wilkin T.J., Gross R., Krambrink A., Coakley E., Greaves W.L., Zolopa A., Reichman R., Godfrey C., Hirsch M., Kuritzkes D.R. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211. J. Infect. Dis. 2007, 196:304-312.
7. Hosoya N., Su Z., Wilkin T., Gulick R.M., Flexner C., Hughes M.D., Skolnik P.R., Giguel F., Greaves W.L., Coakley E., Kuritzkes D.R. Assessing human immunodeficiency virus type 1 tropism: comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions. J. Clin. Microbiol. 2009, 47:2604-2606.
8. Hwang S.S., Boyle T.J., Lyerly H.K., Cullen B.R. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 1991, 253:71-74.
9. Japour A.J., Fiscus S.A., Arduino J.M., Mayers D.L., Reichelderfer P.S., Kuritzkes D.R. Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. J. Clin. Microbiol. 1994, 32:2291-2294.
10. Johnson V.A., Merrill D.P., Videler J.A., Chou T.C., Byington R.E., Eron J.J., D'Aquila R.T., Hirsch M.S. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J. Infect. Dis. 1991, 164:646-655.
11. Kirchherr J.L., Lu X., Kasongo W., Chalwe V., Mwananyanda L., Musonda R.M., Xia S.M., Scearce R.M., Liao H.X., Montefiori D.C., Haynes B.F., Gao F. High throughput functional analysis of HIV-1 env genes without cloning. J. Virol. Methods 2007, 143:104-111.
12. Kollmann C., Tremblay C., Giguel F., Chou T.C., Hirsch M.S. In vitro anti-HIV-1 synergy between non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz. Antivir. Ther. 2001, 6:143-144.
13. Koot M., Keet I.P., Vos A.H., de Goede R.E., Roos M.T., Coutinho R.A., Miedema F., Schellekens P.T., Tersmette M. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann. Intern. Med. 1993, 118:681-688.
14. Meyerhans A., Vartanian J.P., Wain-Hobson S. DNA recombination during PCR. Nucleic Acids Res. 1990, 18:1687-1691.
15. Ndung'u T., Sepako E., McLane M.F., Chand F., Bedi K., Gaseitsiwe S., Doualla-Bell F., Peter T., Thior I., Moyo S.M., Gilbert P.B., Novitsky V.A., Essex M. HIV-1 subtype C in vitro growth and coreceptor utilization. Virology 2006, 347:247-260.
16. Novitsky V., Smith U.R., Gilbert P., McLane M.F., Chigwedere P., Williamson C., Ndung'u T., Klein I., Chang S.Y., Peter T., Thior I., Foley B.T., Gaolekwe S., Rybak N., Gaseitsiwe S., Vannberg F., Marlink R., Lee T.H., Essex M. Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design?. J. Virol. 2002, 76:5435-5451.
17. O'Doherty U., Swiggard W.J., Malim M.H. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J. Virol. 2000, 74:10074-10080.
18. Reeves J.D., Coakley E., Petropoulos C.J., Whitcomb J.M. An enhanced sensitivity Trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5. J. Viral Entry 2009, 3:94-102.
19. Rusconi S., Merrill D.P., La Seta-Catamancio S., Citterio P., Offord R.E., Hirsch M.S. Effective inhibition of HIV-1 isolated from patients with acute primary HIV-1 infection by aminooxypentane-RANTES. AIDS 1999, 13:1144-1145.
20. Schuitemaker H., Koot M., Kootstra N.A., Dercksen M.W., de Goede R.E., van Steenwijk R.P., Lange J.M., Schattenkerk J.K., Miedema F., Tersmette M. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J. Virol. 1992, 66:1354-1360.
21. Thibor I., Lockman S., Smeaton L.M., Shapiro R.M., Wester C., Heymann S.J., Gilbert P.B., Stevens L., Peter T., Kim S., van Widenfelt E., Moffat C., Ndase P., Arimi P., Kebaabetswe P., Mazonde P., Makhema J., McIntosh K., Novitsky V., Lee T.H., Marlink R., Lagakos S., Essex M. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana. JAMA 2006, 296:794-805. for the Mashi Study Team.
22. Thomas J.A., Ott D.E., Gorelick R.J. Efficiency of human immunodeficiency virus type 1 postentry infection processes: evidence against disproportionate numbers of defective virions. J. Virol. 2007, 81:4367-4370.
23. Tremblay C.L., Giguel F., Chou T.C., Dong H., Takashima K., Hirsch M.S. TAK-652, a novel CCR5 inhibitor, has favourable drug interactions with other antiretrovirals in vitro. Antivir. Ther. 2005, 10:967-968.
24. Tremblay C.L., Poulin D.L., Hicks J.L., Selliah S., Chamberland A., Giguel F., Kollmann C.S., Chou T.C., Dong H., Hirsch M.S. Favorable interactions between enfuvirtide and 1-beta-d-2,6-diaminopurine dioxolane in vitro. Antimicrob. Agents Chemother. 2003, 47:3644-3646.
25. Trouplin V., Salvatori F., Cappello F., Obry V., Brelot A., Heveker N., Alizon M., Scarlatti G., Clavel F., Mammano F. Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay. J. Virol. 2001, 75:251-259.
26. Van Baelen K., Vandenbroucke I., Rondelez E., Van Eygen V., Vermeiren H., Stuyver L.J. HIV-1 coreceptor usage determination in clinical isolates using clonal and population-based genotypic and phenotypic assays. J. Virol. Methods 2007, 146:61-73.
27. Whitcomb J.M., Huang W., Fransen S., Limoli K., Toma J., Wrin T., Chappey C., Kiss L.D., Paxinos E.E., Petropoulos C.J. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob. Agents Chemother. 2007, 51:566-575.